Odne, an EPFL and ETHZ spinoff, raises CHF 4,2 Million in Series A

Odne’s story began through a close collaboration between leading researchers at EPFL and ETHZ, who sought to address long-standing clinical challenges in endodontic therapy. With over CHF 4.2 million raised in its Series A1 round — including support from ZEISS Ventures — and several FDA-cleared products now entering the U.S. market, the medtech company is poised to make a significant impact globally.

Odne AG, headquartered in Dübendorf, Switzerland, is emerging as a game-changing force in the field of endodontics — and its origins reflect the depth and rigor of Swiss scientific research. Founded in 2018, Odne is a spin-off from two of the world’s most prestigious scientific and engineering institutions: the Swiss Federal Institute of Technology in Lausanne (EPFL) and the Swiss Federal Institute of Technology in Zurich (ETH Zürich).
Leveraging this academic foundation, Odne licensed several patented technologies developed in the labs of these institutions, transforming them into a fully integrated solution designed to simplify, enhance, and modernize root canal treatment.
This scientific rigor continues to shape Odne’s strategy. The company has developed a proprietary Root Preservation Therapy (RPT) platform — a minimally invasive approach that includes Odne®Clean, Odne®Fill, and Odne®Cure. Together, these innovations aim to raise the standard of care in endodontics, offering improved outcomes for both specialists and general practitioners. The platform’s foundations in academic research give it a unique edge: the technologies are not only clinically sound but also scientifically validated, scalable, and thoughtfully engineered for real-world use.
Its success also reinforces the critical role of Swiss academic institutions in driving innovation beyond the lab and into life-changing medical technologies.

Source: Odne |  📸 Odne